Hermeus Flies Quarterhorse Mk 1 at Edwards Air Force Base
Quarterhorse Mk 1 flight redefines U.S. aircraft development pace and unlocks next steps toward hypersonic aircraft.
EDWARDS AIR FORCE BASE, Calif., May 27, 2025--(BUSINESS WIRE)--Hermeus, a venture capital-backed aerospace and defense technology company specializing in high-speed aircraft, announced today the flight of its Quarterhorse Mk 1 aircraft. This milestone is a significant step in Hermeus' development of high-Mach and hypersonic aircraft. With this flight, Hermeus demonstrated a rapid development pace, advancing Hermeus' mission to operationalize hypersonic technologies.
"Mk 1 has redefined the pace of developing and flying new aircraft," said AJ Piplica, CEO and Co-Founder of Hermeus. "I'm incredibly proud of what our team has accomplished. We've proven the viability of our iterative development approach. But this is just the start. We have much more to do as the bar rises for the next iteration."
Quarterhorse Mk 1 went from clean sheet to flight-ready in a little over a year. The primary focus of the test campaign was validate high-speed takeoff and landing of a large uncrewed aircraft. The aircraft's unique configuration — driven by high-speed flight — makes basic operations of takeoff and landing distinctly challenging.
"Industry partnerships continue to have an important role in the development and test of disruptive and innovative capabilities for our warfighters," commented Major General Scott Cain, Commander of Air Force Test Center. "The promise of routine hypersonic flight is an exciting capability for the joint team."
Data from the campaign has validated design and performance models, including aerodynamics, stability and control. Testing also validated performance of vehicle subsystems including propulsion, fuel systems, hydraulics, power, thermal management, avionics, flight software, telemetry, flight termination and command and control.
"The real-world flight data from Mk 1 provides significant technical value that we're rolling into our next aircraft," said President and Co-Founder Skyler Shuford. "Moreover, the team has accomplished this milestone on a challenging timeline while operating within the overall aerospace ecosystem — all to support rebuilding America's lost capability to quickly develop brand-new, full-scale jets."
Quarterhorse Mk 1 is the first in a series of uncrewed aircraft on Hermeus' iterative development roadmap. The approach emphasizes 'hardware richness' – building multiple prototypes in quick succession, allowing the team to take well-managed technical risk.
The team is actively reviewing data and integrating lessons learned into Hermeus' next iteration, Quarterhorse Mk 2, currently being manufactured at Hermeus' headquarters in Atlanta. The scale of an F-16, Quarterhorse Mk 2 is a high-Mach aircraft designed to de-risk uncrewed supersonic flight. It is on-track to fly late this year.
Hermeus is a venture capital-backed aerospace and defense technology company founded to radically accelerate aviation. In the near-term, the business is focused on building high-speed products that sustainably deliver asymmetric advantage to the Department of Defense and allied partners. Utilizing an iterative development approach to aircraft, Hermeus' high-Mach and hypersonic aircraft aim to deliver capabilities at a pace not seen in the U.S. since the 1950s.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250527795669/en/
Contacts
Melissa Price, Griffin Communications Groupmelissaprice@griffincg.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
China's J-36 Very Heavy Stealth Tactical Jet Photographed Head-On For First Time
New imagery of China's 'J-36' very heavy tactical 6th generation jet has just emerged out of China. The photos shows a long-awaited perspective of the aircraft — taken from the front — that confirms our analysis that the aircraft features a very large and broad bubble canopy to go atop its equally broad nose section. Under that canopy would be two crew sitting side-by-side, similar to the F-111 and Su-34's arrangement, among others. The image also offers a view of the dorsal inlet on the three-engined aircraft, along with its diverterless supersonic inlet (DSI) 'hump,' which appears very large here. Overall, the photos serve as a reminder of just how big this aircraft is. Like many tailless designs, especially stealthy ones, they can look far smaller from the side than from the front, top or bottom. While we have become accustomed to the J-36's modified delta planform, the head-on perspective really underlines the proportions and mass of Chengdu's next-generation tactical jet design. In the imagery, we can also just make out the J-36's lower trapezoidal air inlets, similar to those found on the F-22, as well as one of the jet's unique large aperture electro-optical windows on the side of the nose. That fixture is seen glaring gold in the low-angle light. As is often the case, we must note that the imagery appears authentic, but we cannot be certain of that. Still, it was only a matter of time until we got a head-on angle of the J-36 and this screenshot of a DSLR camera screen (you can see the smart phone's lenses in the reflection) goes along with the progression of 'leaks' out of China we have come accustomed to over many years when it comes to new military aircraft designs. Very interesting but strange frontal view of the CAC J-36, which due to the 'merging' of the top air intake, DSI bump and the wide cockpit makes it look even wider … — @Rupprecht_A (@RupprechtDeino) May 31, 2025 Çin'in Kuyruksuz Savaş Uçağı J-36'nın son test uçuşuna ait görüntüler ortaya çıktı — Times of Defence (@timesofdefencee) May 31, 2025 This new imagery also comes just days after we got the clearest look at Shenyang's smaller, but still heavy-weight 6th generation fighter aircraft, referred to unofficially by a number of designations, including J-XDS and J-50. Not only do we get a more detailed underside view, but we also get a full side-on shot, which shows just how blended the canopy of the aircraft is with its upper fuselage, as well as a better look at the profile of its huge nose. The bottom view gives us a better look at the weapons bay arrangement, as well as its F-22-like nozzle configuration. We can also confirm an EO/IR blister (without its glass) under the nose. The aircraft looks to feature a single pilot/crew. The small side doors where a side weapons bay would likely go remain a bit of a mystery. The aircraft's unique swiveling wingtip control surfaces are also very clear here. Once again, the profile of the nose is striking, and it clearly can accommodate a very large and powerful AESA radar. You can read our very in-depth analysis on these two aircraft, including the knowns and the unknowns surrounding them, which still proves entirely accurate, at this link. Both aircraft were 'unofficially unveiled' via a series of videos and images spilling out of the country of presumably their first test flights back on December 26th, 2024. As we have stated since they first appeared, by summer we will likely have a look at all angles of both aircraft, and in increasing definition, based on how the flow of images of new high-profile military aircraft have historically appeared out of China. So stay tuned for more. Contact the author: Tyler@
Business Wire
2 hours ago
- Business Wire
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ('Avistone'), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study Abstract Number For Publication: 8632 Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic Location: Poster Board, 112 Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common 'off-target' mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ('Avistone') is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.
Business Wire
4 hours ago
- Business Wire
BIOSIG TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of BioSig Technologies, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of BioSig Technologies, Inc. (NasdaqCM: BSGM) and Streamex Exchange Corporation. Upon closing of the proposed transaction, current BioSig shareholders and holders of common stock equivalents will hold 25% of the fully diluted BioSig common stock outstanding. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to BioSig shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
